Showing results (141-150 of 279) with videos related to

Sort By:
Pageof 28
Cancer Biomarkers : Section a of Disease Markers|April 2, 2025
Multi-cancer early detection tests: Attributes for clinical implementationJon O Ebbert, Ernest T Hawk, Christopher V Chambers, et al.
European Urology Oncology|July 6, 2019
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical TrialAndrew J Armstrong, Ping Lin, Celestia S Higano, et al.
Urology|July 31, 2013
Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancerTomasz M Beer, Paul F Schellhammer, John M Corman, et al.
Urology|May 8, 2007
Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsyStephen E F Spurgeon, Solange Mongoue-Tchokote, Lauren Collins, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomyTomasz M Beer, Anne Myrthue, Mark Garzotto, et al.
Life (Basel, Switzerland)|August 29, 2024
Shifting the Cancer Screening Paradigm: Developing a Multi-Biomarker Class Approach to Multi-Cancer Early Detection TestingJohn B Kisiel, Jon O Ebbert, William R Taylor, et al.
The Oncologist|October 25, 2024
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT studyTomasz M Beer, Daniel J George, Neal D Shore, et al.
The Prostate|October 30, 2009
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicityDavid Z Qian, Brooks L S Rademacher, Janet Pittsenbarger, et al.
Frontiers in Cell and Developmental Biology|November 25, 2021
HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-InhibitionHao Geng, Hyun-Kyung Ko, Janet Pittsenbarger, et al.
Health and Quality of Life Outcomes|June 25, 2017
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trialNancy Devlin, Michael Herdman, Marco Pavesi, et al.
Pageof 28